## **EDITORIAL**



## Adding (Viral) Insult to (Smoke) Injury may Prolong COPD Changes After Smoking Cessation

Stavros Garantziotis<sup>1</sup>

Accepted: 30 September 2022

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022

The COVID-19 pandemic has made once again painfully clear that viral infections play an important adverse role in the life of COPD patients [1]. Viral infections are a risk factor for acute exacerbation of COPD [2] and are associated with a prolonged course of COPD exacerbation [3]. On the other hand, COPD patients are at increased risk for viral infections [2] and suffer from prolonged symptoms after viral infections; for example, COPD is a risk factor for persisting symptoms after COVID19 [4, 5]. Cigarette smoke dampens antiviral signaling in small airway epithelial cells by disrupting toll-like receptor signaling [6] and increases susceptibility to viral infection in lung epithelial cells by upregulating viral endocytosis [7]. Thus, viral infections and COPD are connected in a vicious cycle of mutual reinforcement and increased susceptibility.

Most research to date has focused on the acute impact of viral infections on COPD. Much less is known about the potential chronic impact of recurrent viral infections in COPD development and persistence. This gap is addressed by the work of Li et al., in this issue of LUNG [8]. The authors utilize a cigarette smoke/immune activation (through poly-I:C administration) model, to demonstrate that combination exposure exacerbates inflammatory and remodeling changes beyond what either exposure alone achieves. Furthermore, they demonstrate these effects to be more persistent in the case of co-exposure: in this model, inflammatory and remodeling changes persisted for several weeks even after smoke exposure and poly-I:C administration were stopped [8]. This is a significant finding which may have major implications in the prognosis of COPD patients even after smoking cessation.

There are obvious caveats in extrapolating findings of an animal study into the clinical arena. Mouse lungs do not share exact anatomical details with humans [9]. Furthermore, in this study the authors utilized a recurrent exposure to a TLR3 agonist (i.e., poly-I:C) as opposed to actual viral infection. Nevertheless, the results are intriguing and raise important questions about the impact of chronic or recurrent viral infections in the progression of COPD.

How can viral infections lead to progressive COPD? Chronic, low level viral infection leads to a persistent innate immune activation that in turn leads to chronic lung disease [10]. In fact, viral infections can lead to a decline in lung function even in the absence of an exacerbation [11]. In COPD, there is evidence that some patients may be harboring chronic viral infections [12, 13] although this is somewhat controversial [2]. Cigarette smoke exacerbates virus-induced pulmonary innate immune and remodeling responses [14] and may thus potentiate these effects in the case of COPD patients who are active smokers. Viral infections may also lead to weakening of antimicrobial defenses in COPD patients [2, 15] and thus induce changes in the lung microbiome, which may persist beyond the acute infection, thereby causing persistent inflammation. It is also possible that a combined exposure to cigarette smoke and viral infection potentiates airway remodeling to such extent [16, 17], that it prolongs or prohibits full functional recovery. Finally, chronic or recurrent viral infections may alter lung cellular metabolism to an extent that impacts regenerative capacity of the lung. This has been observed, for example, in patients with HIV infection, which is notoriously associated with COPD development [18].

In conclusion, viral infections may potentiate cigarette smoke-induced injury and significantly prolong inflammation and airway remodeling, even after smoking cessation. The paper by Li et al. (8) supports that viral infections in COPD patients can cause more than just a temporary setback. Perhaps it is time to focus more on the COPD lung

Stavros Garantziotis garantziotis@niehs.nih.gov

<sup>&</sup>lt;sup>1</sup> Division of Intramural Research National Institute of Environmental Health Sciences, 111 TW Alexander Dr, Research Triangle Park, Durham 27709, USA

virome and find ways to monitor and treat viral infections in these patients, in order to give their lungs a chance to heal.

**Funding** This work has been supported by funding from the Division of Intramural Research National Institute of Environmental Health Sciences (ES102605).

## References

- Christenson SA, Smith BM, Bafadhel M, Putcha N (2022) Chronic obstructive pulmonary disease. Lancet 399(10342):2227–2242
- Linden D, Guo-Parke H, Coyle PV, Fairley D, McAuley DF, Taggart CC et al (2019) Respiratory viral infection: a potential "missing link" in the pathogenesis of COPD. Euro Respir Rev 28(151):180063
- Gunasekaran K, Ahmad M, Rehman S, Thilagar B, Gopalratnam K, Ramalingam S et al (2020) Impact of a positive viral polymerase chain reaction on outcomes of chronic obstructive pulmonary disease (COPD) exacerbations. Int J Environ Res Public Health 17(21):8072
- Fumagalli C, Zocchi C, Tassetti L, Silverii MV, Amato C, Livi L et al (2022) Factors associated with persistence of symptoms 1 year after COVID-19: a longitudinal, prospective phone-based interview follow-up cohort study. Eur J Intern Med 97:36–41
- Aranda J, Oriol I, Martin M, Feria L, Vazquez N, Rhyman N et al (2021) Long-term impact of COVID-19 associated acute respiratory distress syndrome. J Infect 83(5):581–588
- Duffney PF, McCarthy CE, Nogales A, Thatcher TH, Martinez-Sobrido L, Phipps RP et al (2018) Cigarette smoke dampens antiviral signaling in small airway epithelial cells by disrupting TLR3 cleavage. Am J Physiol Lung Cell Mol Physiol 314(3):L505–L513
- Duffney PF, Embong AK, McGuire CC, Thatcher TH, Phipps RP, Sime PJ (2020) Cigarette smoke increases susceptibility to infection in lung epithelial cells by upregulating caveolin-dependent endocytosis. PLoS ONE 15(5):e0232102
- Mei X, Lu R, Cui L, Tian Y, Zhao P, Li J (2022) Poly I: C exacerbates airway inflammation and remodeling in cigarette smokeexposed mice. Lung. 21:2149

- 9. Irvin CG, Bates JH (2003) Measuring the lung function in the mouse: the challenge of size. Respir Res 4:4
- Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH et al (2008) Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med 14(6):633–640
- Stolz D, Papakonstantinou E, Grize L, Schilter D, Strobel W, Louis R et al (2019) Time-course of upper respiratory tract viral infection and COPD exacerbation. Euro Respir J. 54(4):1900407
- Sikkel MB, Quint JK, Mallia P, Wedzicha JA, Johnston SL (2008) Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr Infect Dis J 27(10 Suppl):S63-70
- Hogg JC (2001) Role of latent viral infections in chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med 164(10 Pt 2):S71–S75
- Kang MJ, Lee CG, Lee JY, Dela Cruz CS, Chen ZJ, Enelow R et al (2008) Cigarette smoke selectively enhances viral PAMPand virus-induced pulmonary innate immune and remodeling responses in mice. J Clin Investig 118(8):2771–2784
- Mallia P, Footitt J, Sotero R, Jepson A, Contoli M, Trujillo-Torralbo MB et al (2012) Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186(11):1117–1124
- Larcombe AN, Iosifidis T, Foong RE, Berry LJ, Stumbles PA, Strickland DH et al (2022) Exacerbation of chronic cigarettesmoke induced lung disease by rhinovirus in mice. Respir Physiol Neurobiol 298:103846
- Foronjy RF, Dabo AJ, Taggart CC, Weldon S, Geraghty P (2014) Respiratory syncytial virus infections enhance cigarette smoke induced COPD in mice. PLoS ONE 9(2):e90567
- Cribbs SK, Crothers K, Morris A (2020) Pathogenesis of HIV-Related Lung Disease: Immunity, Infection, and Inflammation. Physiol Rev 100(2):603–632

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.